Aktuelle medikamentöse Therapie kolorektaler Karzinome – Standards im adjuvanten und im metastasierten Stadium

Autor:	Dirk Jäger, Annika Siegmund
Rok vydání:	2010
Předmět:	Oncology medicine.medical_specialty Bevacizumab Cetuximab business.industry General Medicine digestive system diseases Oxaliplatin Irinotecan Capecitabine Internal medicine medicine Adjuvant therapy Panitumumab business Survival rate medicine.drug
Zdroj:	Der Klinikarzt. 39:456-460
ISSN:	1439-3859 0341-2350
Popis:	Combined therapy according to the FOLFOX protocol is of advantage to Stage III colocarcinoma adjuvant stage patients. In case of a contraindication it is also possible to abstain from oxaliplatin. In such cases it would be practicable to employ the oral fluoropyrimidine capecitabine. Stage II risk patients should also be informed about the possibility of an adjuvant treatment. Every patient in the metastasized stage should be offered - if there are no contraindications - all the available effective preparations such as 5-FU or capecitabine, oxaliplatin, irinotecan. The choice between these substances is decisively determined by their side effects profile. The total survival rate may be statistically extended still further by combining chemotherapy with antibodies (bevacizumab as well as in case of an established KRAS wild-type also cetuximab or panitumumab). In case of patients with limited metastization, it would always be recommendable to consider the possibility of resection.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::c17626b41e9fcc927c26d2ad28080e6f https://doi.org/10.1055/s-0030-1268527 Zobrazit plný text záznamu